Miami, FL (April 14, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into an agreement with Oklahoma State University to evaluate ZofinTM for the treatment of respiratory diseases caused by virus infections of pandemic potential. This study site follows the Company’s earlier announcement of the agreement reached with the Centers for Disease Control and Prevention (“CDC”) to conduct research to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza infection. [Read more…]
NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs) and/or their Secretomes/Exosomes from US Patent Office
April 12, 2021, Baltimore, Maryland – NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced that it has received a patent from the United States Patent Office Patent No.: US 10.967,007 B2 “Cardiac Stem Cells for Cardiac Repair”. The innovation was developed by Dr. Sunjay Kaushal, a pediatric cardiac surgeon, while he was at the University of Maryland, Baltimore and NeoProgen is the exclusive licensee of the newly issued patent. [Read more…]
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19
Golden, Colorado-April 6, 2021 — Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-IIa, randomized, double-blinded, placebo controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19. Our Investigational New Drug (IND) application will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy in patients with moderate to severe COVID-19. [Read more…]
Cytonome cell sorter aids in Parkinson’s treatment
April 6, 2021, BEDFORD, Mass. — Cell sorting technology leader and innovator Cytonome-ST, LLC, has assisted pharmaceutical firm Sumitomo Dainippon Pharma Co., Ltd. to produce enough human stem cells to proceed with a clinical trial of a new treatment aimed at curing Parkinson’s Disease. [Read more…]
Matica Biotechnology, Inc. Announces Groundbreaking for New GMP Facility
Matica Biotechnology, a contract development and manufacturing organization (CDMO) specializing in clinical and commercial production of cell and gene therapies, has broken ground on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located at Providence Park in College Station, Texas. [Read more…]
- « Previous Page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- …
- 119
- Next Page »